Loading...

LYEL LYELL IMMUNOPHARMA INC Product Launches 8-K Filing

LYLL

LYL

LYELL IMMUNOPHARMA INC

(LYEL)

2024 8-K

Show Summary

Show Summary

Merger of Equals

New Clinical Data

Financial Statements

Facility Closure

Financial Results

Acquisition Completed

Clinical Data Release

Board Resignation

Financial Results

Merger Completion

Merger Agreement

Earnings Report

Phase 1 Trial Data Announce...

Earnings Report

Earnings Reports

Repricing of Underwater Opt...

Financial Results Announcement

Investor Presentation

Earnings Report

Annual Meeting of Stockholders

Resignation of Chief Legal ...

Earnings Report

Earnings Reports

External Links:

Lyell Immunopharma, Inc. announced initial clinical and translational data from its Phase 1 trial of LYL797, a ROR1 CAR T-cell product candidate enhanced with anti-exhaustion technology, for the treatment of advanced solid tumors.

AI Assistant

LYELL IMMUNOPHARMA INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.